Key result
Beta-blocker usage in chronic dialysis patients may address cardiovascular diseases, which cause approximately 50% of mortality in this population, though efficacy and safety remain unclear.
Why the study?
Do beta-blockers reduce cardiovascular morbidity and mortality in chronic dialysis patients?
Population
Chronic dialysis patients with advanced chronic kidney disease and cardiovascular comorbidities
Design
Review
Authors
Loading...
Efficacy and safety of beta-blockers remain unclear in dialysis patients; leaves open the need for randomized trials on cardiovascular outcomes.
Do beta-blockers reduce cardiovascular morbidity and mortality in chronic dialysis patients?
Despite the high cardiovascular mortality in chronic dialysis patients and the theoretical benefits of beta-blockers, their efficacy remains unclear and usage is suboptimal due to side effect concerns.
Furgeson et al. (2007) conducted a review in Chronic dialysis. Beta-blockers was evaluated. Beta-blocker usage in chronic dialysis patients may address cardiovascular diseases, which cause approximately 50% of mortality in this population, though efficacy and safety remain unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: